/
/
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
This content is Free Access.
4,164 Views
•
12:41 min
•
December 23, 2022
DOI:
1Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON),University of Antwerp, 2Industrial Vision Lab,University of Antwerp, 3Department of Hepatobiliary Transplantation and Endocrine Surgery,University Hospital Antwerp (UZA), 4Department of Oncology,University Hospital Antwerp (UZA), 5Plasma Lab for Applications in Sustainability and Medicine ANTwerp (PLASMANT),University of Antwerp
Summary
Automatically generated
This protocol describes a semi-automated method for medium- to high-throughput organoid drug screenings and microscope-agnostic, automated image analysis software to quantify and visualize multiparametric, single-organoid drug responses to capture intratumor heterogeneity.
Explore More Videos
MultiparametricTumor OrganoidDrug ScreeningLive-cell ImagingBulk AnalysisSingle-organoid AnalysisStreamlined WorkflowAutomated AnalysisClinically RelevantPatient-derived Tumor OrganoidsPDTOExtracellular MatrixECMDissociationCell SuspensionPDAC OrganoidCulture MediumCell PlatingECM DomesY-27632Organoid Harvesting
Read Article
Cite this Article
Le Compte, M., Cardenas De La Hoz, E., Peeters, S., Smits, E., Lardon, F., Roeyen, G., Vanlanduit, S., Prenen, H., Peeters, M., Lin, A., Deben, C. Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis. J. Vis. Exp. (190), e64434, doi:10.3791/64434 (2022).
Copy